Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Inexpensive drug may improve brain connectivity in people with multiple sclerosis (opens in a new tab)

medicalxpress.com · 2026-11-03

Short answerEvidenceSource

Short answer

Not supported

Not supported.

3 claims go further than the study. One other point was not covered by the paper.

  • 3 overstated
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Not supported

Three of four claims overstate the study. One claim the study doesn't address.

  • 3 overstated
  • 1 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4OverstatedResearchers at Thomas Jefferson University reported that an inexpensive, off-patent compound can improve functioning in people with multiple sclerosis.View evidenceHide evidence

As statedbetter outcomes in a majority of patients

Why this verdict

The abstract profile supports that NAC added to standard care in a small randomized MS study was associated with altered functional connectivity, increased regional glucose metabolism, and correlations with self-reported cognition/attention. But the story’s lead-level framing that an inexpensive, off-patent compound can improve overall functioning, with better outcomes in a majority of patients, goes beyond the abstract evidence: the profile does not verify cost/off-patent status, does not report a majority responder result, and the clinical-function evidence is limited to self-reported cognition/attention correlations rather than demonstrated broad functional improvement.

1

Study evidence

Resting-state functional connectivity showed significant differences after NAC in multiple brain regions (inferior frontal gyrus, inferior temporal gyrus, inferior parietal gyrus, insula, cerebellum, brain stem) compared with standard care.

“Thirty-six patients with mild to moderate MS were randomized to either NAC plus standard of care, or standard of care only.”
2

Study evidence

Self-reported cognition and attention scores significantly correlated with NAC-associated neurophysiological changes (resting-state fMRI functional connectivity and regional FDG PET metabolism), with these correlations reported as stronger in the NAC group compared to controls.

“Clinical symptom questionnaires were also completed at both time points.”
Claim 2 of 4OverstatedThe study added N-acetylcysteine (NAC) to ongoing treatment and found better outcomes in a majority of patients.View evidenceHide evidence

As stateda majority of patients

Why this verdict

The study did add NAC to standard of care, and the abstract reports neurophysiological changes plus cognition/attention-related correlations. However, the profile does not report that a majority of patients had better outcomes, nor does it provide patient-level responder counts. Calling the results 'better outcomes in a majority of patients' therefore overstates what is available at abstract depth.

1

Study evidence

Resting-state functional connectivity showed significant differences after NAC in multiple brain regions (inferior frontal gyrus, inferior temporal gyrus, inferior parietal gyrus, insula, cerebellum, brain stem) compared with standard care.

“Thirty-six patients with mild to moderate MS were randomized to either NAC plus standard of care, or standard of care only.”
2

Study evidence

Self-reported cognition and attention scores significantly correlated with NAC-associated neurophysiological changes (resting-state fMRI functional connectivity and regional FDG PET metabolism), with these correlations reported as stronger in the NAC group compared to controls.

“Clinical symptom questionnaires were also completed at both time points.”
Claim 3 of 4OverstatedUsing PET imaging, the team saw improved functional connectivity in the brain after NAC treatment.View evidenceHide evidence

Why this verdict

The paper profile supports changes in resting-state functional connectivity after NAC, but those functional-connectivity data came from resting-state BOLD fMRI, not PET. PET evidence concerned increased FDG glucose metabolism. The story’s claim therefore conflates imaging modalities and also frames the connectivity changes as 'improved' rather than the abstract’s more cautious 'significant differences/altered functional connectivity.'

1

Study evidence

Resting-state functional connectivity showed significant differences after NAC in multiple brain regions (inferior frontal gyrus, inferior temporal gyrus, inferior parietal gyrus, insula, cerebellum, brain stem) compared with standard care.

“Thirty-six patients with mild to moderate MS were randomized to either NAC plus standard of care, or standard of care only.”
Claim 4 of 4Not coveredThe researchers said larger-scale studies are needed to confirm the findings and determine optimal dosing regimens.View evidenceHide evidence

Why this verdict

The abstract-level profile shows a small randomized sample and limited methodological detail, which is consistent with a need for confirmation, but it does not contain an author statement that larger-scale studies are needed or that optimal dosing regimens must be determined. That specific researcher-position claim is not verifiable from the supplied abstract-depth evidence.

1

Study evidence

Resting-state functional connectivity showed significant differences after NAC in multiple brain regions (inferior frontal gyrus, inferior temporal gyrus, inferior parietal gyrus, insula, cerebellum, brain stem) compared with standard care.

“Thirty-six patients with mild to moderate MS were randomized to either NAC plus standard of care, or standard of care only.”
2

Study evidence

Self-reported cognition and attention scores significantly correlated with NAC-associated neurophysiological changes (resting-state fMRI functional connectivity and regional FDG PET metabolism), with these correlations reported as stronger in the NAC group compared to controls.

“Clinical symptom questionnaires were also completed at both time points.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • NAC dosing in the paper involved weekly IV NAC at 50 mg/kg plus oral 500 mg twice daily on the other six days over roughly 4 ± 2 months.

    The story mentions that optimal dosing needs more study, but it does not report the actual regimen used in the trial or the variable follow-up interval described in the abstract profile.

    From Randomized controlled clinical study (adjunctive NAC vs standard care); Randomized trial (NAC vs standard of care)

  • Resting-state functional connectivity was measured with BOLD fMRI, while FDG PET measured cerebral glucose metabolism.

    The story says PET imaging showed improved functional connectivity, but the profile separates the modalities: BOLD fMRI for functional connectivity and FDG PET for glucose metabolism. This is an important technical distinction that the story does not accurately reflect.

    From Randomized controlled clinical study (adjunctive NAC vs standard care)

  • FDG PET demonstrated increased cerebral glucose metabolism in several brain structures after NAC.

    The story discusses PET imaging but appears to use it to support functional-connectivity improvement; it does not accurately present the PET-specific finding of increased regional glucose metabolism.

    From Randomized controlled clinical study (adjunctive NAC vs standard care)

  • Patient-reported cognition and attention scores correlated with neurophysiological imaging changes in the NAC group compared with controls.

    The story’s broad 'better outcomes' or 'improved functioning' framing does not convey that the clinical-symptom evidence in the abstract was correlational and focused on self-reported cognition and attention, not direct proof of broad functional improvement.

    From Randomized trial (NAC vs standard of care)

  • The supplied abstract profile lacks numerical effect sizes, confidence intervals, detailed statistical thresholds, and multiple-comparison procedures for the imaging findings.

    The story caveats that larger studies are needed and that the result is not definitive, but it does not mention these interpretation-changing statistical-reporting limitations, especially relevant for regional imaging analyses.

    From Randomized controlled clinical study (adjunctive NAC vs standard care)

2 things the story did carry across
  • The study was a randomized clinical comparison of NAC plus standard of care versus standard of care alone in 36 patients with mild-to-moderate multiple sclerosis.
  • The abstract reports significant region-specific functional-connectivity differences after NAC in multiple brain regions.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoTest whether N-acetylcysteine (NAC) added to standard of care alters neurophysiological measures (resting-state functional connectivity on BOLD fMRI and cerebral glucose metabolism on FDG PET) in patients with mild-to-moderate multiple sclerosis compared with standard of care alone.Randomized controlled clinical study (adjunctive NAC vs standard care)Expand

In plain English

Randomized clinical study in 36 patients with mild-to-moderate multiple sclerosis testing whether adjunctive N-acetylcysteine (IV 50 mg/kg weekly + oral 500 mg twice daily other days) versus standard of care alone alters resting-state BOLD functional connectivity and cerebral glucose metabolism (FDG PET) over ~4 ± 2 months. The authors report significant changes in functional connectivity in multiple brain regions and increased FDG uptake in several structures after NAC, with correlations between these imaging changes and self-reported cognition/attention in the NAC group.

Key findings

  • Resting-state functional connectivity showed significant differences after NAC in multiple brain regions (inferior frontal gyrus, inferior temporal gyrus, inferior parietal gyrus, insula, cerebellum, brain stem) compared with standard care.
  • FDG PET demonstrated increased cerebral glucose metabolism in several structures after NAC, including the inferior frontal gyrus and inferior temporal gyrus.
“Thirty-six patients with mild to moderate MS were randomized to either NAC plus standard of care, or standard of care only.”
What this piece can’t prove
  • Abstract provides limited methodological detail (no reporting of statistical thresholds, effect sizes, or multiple comparisons procedures).
  • Small randomized sample (n=36) reported in abstract may limit generalizability and statistical power.
  • Follow-up timing reported as 4 ± 2 months; variability in follow-up intervals could affect outcome assessment but details are not provided.

1 further detail could not be confirmed from the summary.

2human in vivoAssess whether NAC-associated PET/MRI neurophysiological changes are associated with (correlate with) changes/improvements in patient-reported symptoms (especially cognition and attention).Randomized trial (NAC vs standard of care)Expand

In plain English

Within a randomized trial of NAC versus standard of care in 36 patients with mild-to-moderate multiple sclerosis, patient-reported cognition and attention scores collected at baseline and after ~4 months were reported to significantly correlate with NAC-associated changes in resting-state functional connectivity and regional FDG uptake; these correlations were described as stronger in the NAC group versus controls.

Key findings

  • Self-reported cognition and attention scores significantly correlated with NAC-associated neurophysiological changes (resting-state fMRI functional connectivity and regional FDG PET metabolism), with these correlations reported as stronger in the NAC group compared to controls.
“Clinical symptom questionnaires were also completed at both time points.”
What this piece can’t prove
  • Small randomized sample (36 participants) may limit statistical power and generalizability.
  • Potential multiplicity of imaging and questionnaire comparisons increases risk of false positives unless corrected; abstract does not state multiplicity control.
  • Unclear temporal/causal interpretation of the reported associations (whether imaging changes preceded symptom change or vice versa).

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 37 candidate papers

And 31 more candidates considered.